• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20001 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V]
2010     Committee for New Health Technology Assessment (CNHTA) [Glaucoma mini shunt implant surgery]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glasdegib (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2008     Committee for New Health Technology Assessment (CNHTA) [GLA gene, mutation[sequencing]]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Givosiran (acute hepatic porphyria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gilteritinib (AML) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2009     Committee for New Health Technology Assessment (CNHTA) [GFAP gene, mutation[sequencing]]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Geographical mental health map: geographical variation in psychosis and association with environmental factors]
2009     Committee for New Health Technology Assessment (CNHTA) [Genotyping of MDM2 SNP309 polymorphism]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Genomic expression tests in patients with breast cancer: MammaPrint®, Oncotype DX® and Prosigna®]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Genetics development plan in the Basque Country]
2002     Andalusian Health Technology Assessment Area (AETSA) [Genetic testing services for hereditary diseases in Spain: results from a survey - primary research]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Genetic testing in primary dystonia]
2013     Andalusian Health Technology Assessment Area (AETSA) [Genetic testing for predicting treatment response in major depressive disorders]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Genetic testing for lynch syndrome in colorectal cancer and family members]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Genetic sequencing panel for motor-sensory hereditary neuropathy diagnosis]
2010     Andalusian Health Technology Assessment Area (AETSA) [Genetic screening of colorrectal neoplasms through fecal DNA analysis]
2014     Andalusian Health Technology Assessment Area (AETSA) [Genetic diseases in Spain: map of genetic tests available in the national health system]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Genetic counselling in congenital anomalies in the autonomous community of the Basque Country]
2007     Basque Office for Health Technology Assessment (OSTEBA) [Genetic counselling in breast cancer and colon cancer]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [General ultrasound screening for developmental dysplasia of the hip at three months of age: an implementation study]
2008     The Swedish Council on Health Technology Assessment (SBU) [General childhood vaccination against HPV 16 and 18 aimed at preventing cervical cancer]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Gene sequencing of tumours: clinical validity and utility of molecular profiles obtained by next-generation sequencing (NGS) technologies]
2010     Andalusian Health Technology Assessment Area (AETSA) [Gene expression test for breast cancer Oncotype]
2015     Haute Autorite de sante (HAS) [Gene amplification to detect herpes simplex virus (HSV) and varicella-zoster virus (VZV) genomes in cerebrospinal fluid in cases of encephalitis]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Gender-specific differences in drug effects. Exemplary analysis based on beta-adrenoceptor antagonists as cardiac therapy and antidepressants as psychotropic drugs]
2000     Andalusian Health Technology Assessment Area (AETSA) [Gender dysphoria: possible interventions and coverage in Andalusian Health System - systematic review, economic evaluation]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gemtuzumab ozogamicin (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2010     Institute for Clinical Effectiveness and Health Policy (IECS) [Gefitinib for the treatment of lung cancer]
2008     Committee for New Health Technology Assessment (CNHTA) [GBA gene, mutation[sequencing]]
2008     Committee for New Health Technology Assessment (CNHTA) [Gastric cancer sentinel node excision]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Gamma Knife versus adapted linear accelerators: A comparison of two radiosurgical applications]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Galsulfase (Naglazyme) for the treatment of mucopolysaccharidosis type VI]
2010     Committee for New Health Technology Assessment (CNHTA) [GALK1 gene mutation analysis[sequencing]]
2010     Committee for New Health Technology Assessment (CNHTA) [GALE gene,mutation[sequencing]]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Galcanezumab (migraine) - Second Addendum to Commission A19-28]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Galcanezumab (migraine) - Addendum to commission A19-28]
2019     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Gait speed as predictor of frailty]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Gait laboratory in patients with gait disorders]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Gadoxetic acid-enhanced magnetic resonance imaging to diagnose focal liver lesions]
2008     Committee for New Health Technology Assessment (CNHTA) [GAA gene, mutation[sequencing]]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Functioning and disability - an evidence map]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Fulvestrant for the treatment of locally advanced ormetastatic breast cancer]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Fully bioresorbable scaffolds for coronary artery disease: systematic review]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Fully bioresorbable drug-eluting coronaryscaffolds: A review]
2001     Finnish Office for Health Care Technology Assessment (Finohta) [From traditional film-based radiology to digital imaging: a simplified model for costing radiology services in small and medium-sized radiology units]
1999     Finnish Office for Health Care Technology Assessment (Finohta) [From science to practice - systematic reviews in health care]
2003     The Netherlands Organisation for Health Research and Development (ZonMw) [From efficacy to effectiveness in cancer research]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fremanezumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fremanezumab (migraine) - Addendum to Commission A19-44]
2005     Andalusian Health Technology Assessment Area (AETSA) [Framework for the assessment of genetic testing in the Andalusian public health system]
2021     Canary Health Service [Framework for relations between the Spanish Network of HTA agencies of the NHS with industry]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Fractional flow-reserve by intracoronary pressure guidewire in patients with acute coronary syndrome]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Fractional flow reserve in coronary artery]
2015     Haute Autorite de sante (HAS) [Fractional flow reserve (FFR) measurement during coronary angiography]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostemsavir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostamatinib (chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Food in diabetes]
2007     Health Council of the Netherlands Gezondheidsraad (GR) [Food allergy]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Follow-up visits from nurses after discharge from multidisciplinary pain centre - a health technology assessment]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Follow-up in gynaecological cancer patients - a health technology assessment]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Follow-Up for gynecological cancer]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Foetal growth retardation at term: induction of labour or not? A comparison of maternal and neonatal outcome, maternal quality of life and costs (DIGITAT). The Disproportionate Intrauterine Growth Intervention Trial At Term (DIGITAT)]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [FOAM-study. Cost minimization study comparing surgery versus duplex guided foam sclerotherapy of varicose veins: a randomized controlled study]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-79]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-15]
2010     Finnish Office for Health Care Technology Assessment (Finohta) [Fluorescence cystoscopy in diagnosis and management of superficial bladder cancer]
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Flashglucose monitoring system (Freestyle Libre, Abbott), report updated April 8 2020]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2015     Norwegian Knowledge Centre for the Health Services (NOKC) [First aid training may improve first aid skills]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Fingolimod for relapsing/remitting multiple sclerosis (RRMS)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (new therapeutic indication) - Addendum to Commission A15-48]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (multiple sclerosis in children and adolescents) - Addendum to Commission A18-87]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Financing procedures in primary care adequate for resources and efficiency, by means of adjusted clinical groups (ACG)]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [FilmArray® in Acute Respiratory Infections and Sepsis]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Filgotinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2014     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Field evaluation of the initial treatment of STEMI in Quebec's hospitals - phase 2]
2013     Andalusian Health Technology Assessment Area (AETSA) [Fidaxomicin for the treatment of clostridium difficile infection]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fidaxomicin (Clostridioides difficile infection) - Benefit assessment according to §35a Social Code Book V]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Fibromyalgia and chronic fatigue syndrome: recommendations on diagnosis and treatment]
2010     Committee for New Health Technology Assessment (CNHTA) [Fiberoptic endoscopic evaluation of swallowing]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Fetoscopic laser photocoagulation in twin-twin transfusion syndrome]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Fetal neurosonography in suspected central nervous system abnormalities]
2012     Finnish Office for Health Care Technology Assessment (Finohta) [Fetal intrapartum surveillance - Does STAN improve safety? A meta-analysis]
2016     The Swedish Council on Health Technology Assessment (SBU) [Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Spectrum Disorders (FASD) – conditions and interventions]
2013     The Regional Health Technology Assessment Centre (HTA-centrum) [Fertility preservation in girls and young women in whom potentially gonadotoxic treatment is planned or has been performed]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Ferrara corneal ring for treating keratoconus]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fenfluramine (Dravet syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2010     The Regional Health Technology Assessment Centre (HTA-centrum) [Fenestrated aortic repair of aortic aneurysm]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fedratinib (myelofibrosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Federal structures of the prevention of alcohol misuse among children and youths]